White label ELPA - ClinicalTrials.eu

Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

Recruiting

2 1 1 1
Investigated diseases:
- Chronic myeloid leukaemia
Investigated drugs:
- Asciminib Hydrochloride
Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer
- Non-small cell lung cancer metastatic
Investigated drugs:
- Pembrolizumab
+10
A Phase 2 Study of JNJ-79635322 in Patients with Relapsed or Refractory Multiple Myeloma

Recruiting

2 1 1
Investigated diseases:
- Plasma cell myeloma refractory
Investigated drugs:
- IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

Recruiting

3 1 1
Investigated drugs:
- Remibrutinib
Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer stage III
Investigated drugs:
- Durvalumab
+8
A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Recruiting

3 1 1 1
Investigated drugs:
+14
Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

Recruiting

2 1 1
Investigated diseases:
- Oesophageal squamous cell carcinoma
Investigated drugs:
- Ifinatamab Deruxtecan
A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Recruiting

3 1 1 1
Investigated drugs:
- Guselkumab
- Risankizumab
+7
Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Recruiting

2 1
Investigated diseases:
- Rheumatoid arthritis
Investigated drugs:
- Ro7790121
+1
Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

Recruiting

2 1 1
Investigated diseases:
- Neoplasm

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies